# Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

> **NCT06023459** · PHASE3 · COMPLETED · sponsor: **Yih-Ing Hser** · enrollment: 140 (actual)

## Conditions studied

- Opioid-Related Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders

## Interventions

- **DRUG:** Injectable extended-release buprenorphine
- **DRUG:** Sublingual buprenorphine-naloxone

## Key facts

- **NCT ID:** NCT06023459
- **Lead sponsor:** Yih-Ing Hser
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-14
- **Primary completion:** 2025-11-04
- **Final completion:** 2026-01-14
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023459, "Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06023459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*